Welcome, Guest. Please login or register.
November 28, 2021, 10:44:42 pm

Login with username, password and session length


  • Total Posts: 327
  • Total Topics: 183
  • Online Today: 32
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 9
Total: 9


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Keytruda shatters stats on lung cancer long-term survival  (Read 2856 times)

Offline iana5252

  • Administrator
  • Newbie
  • *****
  • Posts: 21
    • View Profile
Keytruda shatters stats on lung cancer long-term survival
« on: June 07, 2019, 09:28:57 am »
This news came out of ASCO, a big cancer doctor gathering in Chicago held in June every year. Here's some of Cancer Health's coverage of the news.


The checkpoint inhibitor Keytruda (pembrolizumab) continues to be a safe and effective treatment for non-small-cell lung cancer (NSCLC), leading to an improvement in overall survival at five years, according to long-term follow-up data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

In the KEYNOTE-001 study, which began enrollment at the dawn of the immunotherapy era, nearly a quarter of people who had not previously been treated with chemotherapy and about 15% of treatment-experienced patients were still alive five years later, reported Edward Garon, MD, of the UCLA David Geffen School of Medicine in Los Angeles. In contrast, people treated with chemotherapy historically had a five-year survival rate of around 5% before the arrival of immunotherapy.

β€œThe uniformly negative outlook that has been associated with a diagnosis of advanced non-small-cell lung cancer is certainly no longer appropriate,” Garon said. β€œThe fact that we have patients on this trial that are still alive after seven years is quite remarkable. We also have evidence that most patients who are doing well after two years on pembrolizumab live for five years or more.”

« Last Edit: June 07, 2019, 09:35:12 am by iana5252 »


© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.